LITHIUM
Manufacturer: Advagen Pharma Ltd
Score: 141.0
Lithium is a mood-stabilizing agent used for the treatment of bipolar I disorder. It is indicated for the treatment of acute manic and mixed episodes, as well as maintenance treatment. The drug has a narrow therapeutic index, and its use requires careful monitoring of serum lithium concentrations. Lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient and has several important safety considerations, including the risk of lithium toxicity, serotonin syndrome, and hypothyroidism. The recommended starting dosage for adults and pediatric patients over 30 kg is 8 mEq of lithium (5 mL) three times daily, with adjustments based on serum lithium concentrations and clinical response. Special population considerations include use during pregnancy, pediatric use, and geriatric use, with careful monitoring and dose adjustments as needed.
Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations.
Dose adjustments should be made based on serum lithium concentrations and clinical response, with careful monitoring and adjustments as needed.
8 mEq of lithium (5 mL) three times daily
8 mEq (5 mL) twice daily for patients 20-30 kg
8 mEq of lithium (5 mL) two to three times daily
8 mEq (5 mL) twice daily for patients 20-30 kg